SapiensBio is a data-driven drug discovery company headquartered in South Korea with a U.S. office. We focus on discovering novel drug candidates for the treatment of severe diseases with high unmet medical need by integrating machine learning and experimental biology to identify novel targets and generate drug-like chemical matter. Through single-cell RNA-seq analysis of lung tissue from IPF patients, ARPC2 was identified as a novel therapeutic target. In vitro studies confirmed ARPC2 is upregulated in lung fibrosis and is both necessary and sufficient to drive a fibrotic response. ARPC2 acts via modulation of MRTF nuclear translocation and activity. We have developed a series of novel, orally bioavailable small-molecule ARPC2 modulators with demonstrated anti-fibrotic activity in vitro and in vivo. A selective compound with a favorable safety profile (90-day oral tox in rats and dogs) has been nominated as a clinical candidate for IPF and other fibrotic diseases.